Development and Pilot Testing of a Cognitive-Behavioral Therapy Digital Service for Body Dysmorphic Disorder

Wilhelm, Sabine; Weingarden, Hilary; Greenberg, Jennifer L.; McCoy, Thomas H.; Ladis, Ilana; Summers, Berta J.; Matic, Aleksandar; Harrison, Oliver

doi:10.1016/j.beth.2019.03.007

Cited by 48 publications

(32 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Guided self-management of symptoms, e.g. via online delivered psychotherapy or smartphones, could bridge this gap, addresses many of the logistical and shame related barriers we identified and has already shown promising effects in BDD [53][54][55].…”

Section: Discussionmentioning

confidence: 99%

Treatment utilization and treatment barriers in individuals with body dysmorphic disorder

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background: Although effective treatments are available, most individuals with body dysmorphic disorder (BDD) do not receive an appropriate diagnosis or treatment. We aimed to examine treatment utilization and barriers to treatment, and to identify associated socio-demographic and clinical characteristics. Methods: German individuals completed an online self-report survey of appearance concerns. A sample of N = 429 individuals met criteria for BDD. We examined the frequency of treatment utilization and barriers, analyzed comparisons between treated and untreated individuals and assessed the relationships of socio-demographic and clinical features with mental health treatment utilization and treatment barriers, respectively.Results: Only 15.2% of the individuals with BDD had been diagnosed with BDD, and lifetime rates of mental health treatment were low (39.9%). Individuals endorsed multiple barriers to mental health treatment, especially shame, low perceived need and a preference for cosmetic and medical treatments. Associated features were identified, including age, a BDD diagnosis, body dysmorphic symptom severity, a likely major depressive disorder, prior cosmetic surgery, and insight. Conclusions:The results of this largest study to date highlight that BDD is still underrecognized and undertreated even in a country with extensive mental health care and few financial barriers. We discuss modifiable factors and strategies to foster awareness of BDD in sufferers and professionals to improve treatment dissemination and to reduce treatment barriers.

show abstract

Section: Discussionmentioning

confidence: 99%

Treatment utilization and treatment barriers in individuals with body dysmorphic disorder

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…Another small (n=10) 12-week study by the same group examined the use of smartphone based Cognitive Behavioral Therapy (CBT) for the treatment of BDD. The results indicated that this modality of CBT resulted in good response 90 days post treatment with measures of BDD severity decreasing along with improvement of in BDD insight, functional impairment, and quality of life (Wilhelm et al, 2020). Another study using internet-based CBT reported good outcomes in treating BDD patients as well (La Lima, 2018).…”

Section: Body Dysmorphic Disordermentioning

confidence: 97%

Delusional Misidentification Syndromes: Psychopathology and Culture

Volkan¹

2020

jhms

View full text Add to dashboard Cite

show abstract

“…Recently, Wilhelm et al (2020) developed and tested the first smartphone CBT app for BDD to examine the potential of another low cost, accessible, and standardized BDD intervention. The program was developed with extensive input from BDD patient consultants as well as engineering, design, and clinical psychology experts.…”

Section: Online and Smartphone-based Interventionsmentioning

confidence: 99%

Body dysmorphic disorder: a treatment synthesis and consensus on behalf of the International College of Obsessive-Compulsive Spectrum Disorders and the Obsessive Compulsive and Related Disorders Network of the European College of Neuropsychopharmacology

Castle

Beilharz

Phillips

et al. 2020

International Clinical Psychopharmacology

Self Cite

View full text Add to dashboard Cite

Body dysmorphic disorder (BDD) is characterized by a preoccupation with a perceived appearance flaw or flaws that are not observable to others. BDD is associated with distress and impairment of functioning. Psychiatric comorbidities, including depression, social anxiety, and obsessive-compulsive disorder are common and impact treatment. Treatment should encompass psychoeducation, particularly addressing the dangers associated with cosmetic procedures, and may require high doses of selective serotonin reuptake inhibitors* (SSRI*) and protracted periods to establish full benefit. If there is an inadequate response to SSRIs, various adjunctive medications can be employed including atypical antipsychotics*, anxiolytics*, and the anticonvulsant levetiracetam*. However, large-scale randomized controlled trials are lacking and BDD is not an approved indication for these medications. Oxytocin* may have a potential role in treating BDD, but this requires further exploration. Cognitive-behavioural therapy has good evidence for efficacy for BDD, and on-line and telephone-assisted forms of therapy are showing promise. CBT for BDD should be customized to address such issues as mirror use, perturbations of gaze, and misinterpretation of others’ emotions, as well as overvalued ideas about how others view the individual.

show abstract

Development and Pilot Testing of a Cognitive-Behavioral Therapy Digital Service for Body Dysmorphic Disorder

Cited by 48 publications

References 29 publications

Treatment utilization and treatment barriers in individuals with body dysmorphic disorder

Treatment utilization and treatment barriers in individuals with body dysmorphic disorder

Delusional Misidentification Syndromes: Psychopathology and Culture

Body dysmorphic disorder: a treatment synthesis and consensus on behalf of the International College of Obsessive-Compulsive Spectrum Disorders and the Obsessive Compulsive and Related Disorders Network of the European College of Neuropsychopharmacology

Contact Info

Product

Resources

About